InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

InterCure Ltd.NASDAQ: INCR

Cash & Equivalents · Q4 FY2025 · quarter ended Dec 2025

Cash & equivalents falls 40.7% from a year ago

Cash & equivalents stood at ₪46.47M at the end of Q4 FY2025, down 40.7% from a year earlier. Over 3 fiscal years it compounded at -41.5% a year.

Context

  • Cash & equivalents amounted to 6.7% of total assets at the end of Q4 FY2025, down 3.5 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -40.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
₪46.47M— QoQ
Last fiscal yearDec 2025
₪46.47M-40.7% YoY
Year agoDec 2024
₪78.32M-40.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.7%——
1 year-40.7%——
3-year CAGR-41.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

ILS · from the balance sheet

Latest · FY2025
46.47M ILS
Year-over-year change
-40.7%
4-year CAGR
-30.2%

Cash & Equivalents vs competitors

How INCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -40.7% is the lowest of 9, against a peer median of +21.9%.
  • Cash & equivalents amounts to 6.7% of total assets for INCR, versus a peer median of 66.5%.
INCR Competitors
Cash & Equivalents for INCR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FBIOFortress Biotech, Inc.Mar 2026$255.84M USD+180.1%-23.6%71.7%
AMWLAmerican Well CorporationMar 2026$179.21M USD-19.4%-30.3%55.0%
CAMPCAMP4 Therapeutics CorporationMar 2026$99.21M USD+101.1%—94.1%
INCRInterCure Ltd.Dec 2025₪46.47M ILS-40.7%-41.5%6.7%
BMEABiomea Fusion, Inc.Mar 2026$44.69M USD+24.6%-20.7%96.4%
UNCYUnicycive Therapeutics, Inc.Mar 2026$37.37M USD+89.0%+300.4%58.0%
ASRTAssertio Holdings, Inc.Mar 2026$33.71M USD-3.7%-46.0%16.0%
CRDLCardiol Therapeutics Inc.Mar 2026CA$27.74M CAD+19.1%-21.2%88.1%
HYFTMindWalk Holdings Corp.Jan 2026CA$14.18M CAD+9.8%-29.1%61.2%
Peer median (excluding INCR) —+21.9%-23.6%66.5%

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents196.22M232.59M101.14M78.32M46.47M
Short-term Investments330K205K187K333K209K
Net Receivables37.53M49.51M61.12M180.5M154.47M
Inventory67.88M146.5M106.29M125.33M108.06M
Other Current Assets21.08M94.35M148.78M1.32M2.03M
Total Current Assets336.16M527.49M418.8M391.8M316.75M
Property, Plant & Equipment (Net)86.51M103.13M97.47M105.24M102.81M
Goodwill258.07M284.18M221.08M224.59M219.19M
Intangible Assets00000
Long-term Investments2.57M42.57M1.92M2.15M1.02M
Tax Assets3.02M20.64M24.68M38.37M45.99M
Other Non-current Assets1K022.65M423K4.79M
Total Non-current Assets350.17M450.51M367.81M370.77M373.81M
Total Assets686.32M958.01M786.61M762.57M690.55M
Account Payables64.47M126.07M78.44M77.54M68.14M
Short-term Debt72.28M128.03M88.19M69.44M99.8M
Tax Payables00000
Deferred Revenue2.9M8.06M000
Other Current Liabilities39.42M35.63M8.16M37.97M2.97M
Total Current Liabilities193.58M312.72M225.87M226.75M214.37M
Long-term Debt11.95M99.68M82.2M113.98M59.46M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities223K1.03M841K973K881K
Total Non-current Liabilities33.55M123.81M103.68M138.15M79.83M
Total Liabilities227.13M436.53M329.55M364.9M294.2M
Common Stock623.57M632.03M643.16M658.6M675.6M
Retained Earnings(186.47M)(141.65M)(204M)(277.58M)(314.62M)
Accumulated OCI2.39M2.39M15.95M15.95M15.95M
Other Stockholders Equity8.54M8.54M0019.59M
Minority Interest11.16M20.17M1.95M702K(164K)
Total Equity459.19M521.48M457.06M397.67M396.36M
Total Debt108.91M255.16M195.68M211.4M183.01M
Net Debt(87.31M)22.57M94.54M133.09M136.55M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.